SOLENO THERAPEUT. DL-,001

Soleno Therapeutics’ stock fell to a new 52-week low of $32.51, 33% below last year’s level; the shares lost nearly 14% just in the past week. Despite the slide, the company reported Q4 2025 EPS of $0.80 and revenue of $91.7 million, both above expectations. Jennifer Fulk will become the new chief financial officer at the end of Q1; James Mackaness will remain as an advisor through the end of 2026. Analysts cut their price targets (Oppenheimer 110→80 USD, H.C. Wainwright 120→100 USD) but mostly kept positive ratings. » More on de.investing.com

Solesence has appointed Kevin Cureton as chief executive officer and president; Jess Jankowski will move into a board advisor role and retire on November 21, 2025. Laura Riffner was named chief financial officer. Cureton and Riffner will receive base annual salaries of at least $367,000 and $270,000, respectively, and are eligible for bonuses and stock option awards. » More on de.investing.com

Solesence Inc. reported revenue of $20.36 million for the second quarter of 2025 (up 56% year over year) and EPS of $0.04, while net income rose to $2.7 million. Despite strong margins and federal tax credits, the stock plunged 25.6% after the release, apparently over concerns about weakening demand and tariffs. Management emphasizes operational efficiency and expects a year of record revenue but warns of potential risks to demand, the supply chain and government credits. » More on de.investing.com